 UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, an immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY. 